Vor Biopharma (VOR) Cash from Investing Activities (2020 - 2026)
Vor Biopharma (VOR) reported Cash from Investing Activities of -$263.2 million for Q1 2026, down 114350.87% year-over-year from N/an in Q1 2025, and down 437.5% quarter-over-quarter from -$49.0 million in Q4 2025.
Vor Biopharma (VOR) Cash from Investing Activities (2020 - 2026) Analysis & Trends
Vor Biopharma (VOR) has 7 years of Cash from Investing Activities data on file, last reported at -$263.2 million in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$263.2 million, down 114350.87% year-over-year; the trailing twelve-month figure through Mar 2026 was -$311.8 million (down 692.18% YoY), and the FY2025 annual result was -$48.8 million, down 150.39% from the prior year.
- Cash from Investing Activities slipped to -$263.2 million in Q1 2026 per VOR's latest filing, from -$49.0 million in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $53.0 million in Q2 2024 and troughed at -$263.2 million in Q1 2026.
- A 5-year average of -$14.0 million and a median of -$34000.0 in 2024 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2023 and 2026: Cash from Investing Activities surged 604.77% in 2023, then slumped 114350.87% in 2026.
- A 5-year view of Cash from Investing Activities shows it stood at -$97.0 million in 2022, then soared by 110.65% to $10.3 million in 2023, then plunged by 100.7% to -$72000.0 in 2024, then plunged by 67919.44% to -$49.0 million in 2025, then slumped by 437.5% to -$263.2 million in 2026.
- Business Quant data shows VOR's Cash from Investing Activities at -$263.2 million in Q1 2026, -$49.0 million in Q4 2025, and -$244000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 579,519.10 |
| 10 | Vor Biopharma | 621.09 Mn | 621.09 Mn | - | -263.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -263.24 Mn |
| Mar 31, 2026 | -263.24 Mn |
| Dec 31, 2025 | -48.97 Mn |
| Dec 31, 2025 | -48.97 Mn |
| Sep 30, 2025 | -244,000.00 |
| Sep 30, 2025 | -244,000.00 |
| Jun 30, 2025 | 646,000.00 |
| Jun 30, 2025 | 646,000.00 |
| Mar 31, 2025 | -230,000.00 |
| Mar 31, 2025 | -230,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Dec 31, 2024 | -72,000.00 |
| Sep 30, 2024 | -34,000.00 |
| Sep 30, 2024 | -34,000.00 |
| Jun 30, 2024 | 52.99 Mn |
| Jun 30, 2024 | 52.99 Mn |
| Mar 31, 2024 | 43.97 Mn |
| Mar 31, 2024 | 43.97 Mn |
| Dec 31, 2023 | 10.34 Mn |
| Dec 31, 2023 | 10.34 Mn |